Results 1 to 10 of about 276,787 (297)

Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Frontiers in Pharmacology, 2022
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, some drug use addictions, as well as depression.
Fangyi Zhao, Fangyi Zhao, Ziqian Cheng, Ziqian Cheng, Jingjing Piao, Jingjing Piao, Ranji Cui, Ranji Cui, Bingjin Li, Bingjin Li   +9 more
doaj   +1 more source

The Genetic Underpinnings of Affective Temperaments: Identifying Novel Risk Variants with a Whole Genome Analytical Approach

European Psychiatry, 2022
One reason behind the failure to understand the neurobiological background of affective disorders and develop more effective treatments is their heterogeneity warranting identification of clinically meaningful endophenotypes.
X. Gonda, N. Eszlari, D. Torok, Z. Gal, A. Millinghoffer, P. Antal, G. Juhasz, G. Bagdy   +7 more
doaj   +1 more source

Association of genetic variants of Glutamate Metabotropic Receptor 5 gene and state-anhedonia

European Psychiatry, 2022
Introduction Andedonia is one of the core symptoms of depression. It is known that in case of depressed individuals experiencing anhedonia, the classical antidepressants are often ineffective, thus investigation of this symptom would be essential ...
D. Török, X. Gonda, Z. Gal, N. Eszlari, G. Bagdy, G. Juhasz, P. Petschner   +6 more
doaj   +1 more source

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance Psychedelic compounds, such as psilocybin, have beneficial actions in several psychiatric diseases. They also produce strong alterations of consciousness, which may be a barrier to their widespread use.
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, Anthony B. Cole, S. Thompson   +4 more
semanticscholar   +1 more source

Genetic underpinnings of affective temperaments: a pilot GWAS investigation identifies a new genome-wide significant SNP for anxious temperament in ADGRB3 gene

Translational Psychiatry, 2021
Although recently a large-sample GWASs identified significant loci in the background of depression, the heterogeneity of the depressive phenotype and the lack of accurate phenotyping hinders applicability of findings.
Xenia Gonda, Nora Eszlari, Dora Torok, Zsofia Gal, Janos Bokor, Andras Millinghoffer, Daniel Baksa, Peter Petschner, Peter Antal, Gerome Breen, Gabriella Juhasz, Gyorgy Bagdy   +11 more
doaj   +1 more source

Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems

Frontiers in Cell and Developmental Biology, 2022
Depression has an alarmingly high prevalence worldwide. A growing body of evidence indicates that environmental factors significantly affect the neural development and function of the central nervous system and then induce psychiatric disorders.
Ziqian Cheng, Ziqian Cheng, Jingyun Su, Jingyun Su, Kai Zhang, Huiyi Jiang, Bingjin Li, Bingjin Li   +7 more
doaj   +1 more source

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Molecular Psychiatry, 2021
(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms ...
W. Yao, Qianqian Cao, Shilin Luo, Lujuan He, Chun Yang, Jiaxu Chen, Q. Qi, K. Hashimoto, Ji-chun Zhang   +8 more
semanticscholar   +1 more source

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea

Frontiers in Aging Neuroscience, 2023
BackgroundVortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a ...
Eduardo Cumbo, Michael Adair, Daniel Oudin Åstrom, Michael Cronquist Christensen   +3 more
doaj   +1 more source

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Molecular Psychiatry, 2021
The discovery of robust antidepressant actions exerted by the N -methyl-D-aspartate receptor (NMDAR) antagonist ( R,S )-ketamine has been a crucial breakthrough in mood disorder research.
Yan Wei, Lijia Chang, K. Hashimoto
semanticscholar   +1 more source

The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain

Frontiers in Psychiatry, 2022
Depression is a common and often recurrent illness with significant negative impact on a global scale. Current antidepressants are ineffective for up to one third of people with depression, many of whom experience persistent symptomatology.
Angharad N. de Cates, Angharad N. de Cates, Marieke A. G. Martens, Marieke A. G. Martens, Lucy C. Wright, Lucy C. Wright, Cassandra D. Gould van Praag, Cassandra D. Gould van Praag, Liliana P. Capitão, Liliana P. Capitão, Daisy Gibson, Daisy Gibson, Philip J. Cowen, Philip J. Cowen, Catherine J. Harmer, Catherine J. Harmer, Catherine J. Harmer, Susannah E. Murphy, Susannah E. Murphy   +18 more
doaj   +1 more source